CG
ACAD icon

Cutler Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Cutler Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-800
Closed -$13K – 4827
2022
Q2 		$11K Sell
800
-4,646
-85% -$86.7K ﹤0.01% 3098
2022
Q1 		$131K Sell
5,446
-29,459
-84% -$713K 0.01% 1501
2021
Q4 		$814K Buy
34,905
+27,405
+365% +$551K 0.03% 536
2021
Q3 		$124K Buy
7,500
+7,400
+7,400% +$143K 0.01% 1739
2021
Q2 		$2K Hold
100
– – ﹤0.01% 4920
2021
Q1 		$2K Buy
+100
New +$4.4K ﹤0.01% 4845
2020
Q1 		– Sell
-4,100
Closed -$169K – 3923
2019
Q4 		$175K Buy
4,100
+827
+25% +$36K 0.01% 892
2019
Q3 		$117K Buy
+3,273
New +$99.2K 0.01% 990
2019
Q2 		– Sell
-6,878
Closed -$176K – 4133
2019
Q1 		$184K Buy
6,878
+4,011
+140% +$93.7K 0.02% 679
2018
Q4 		$46K Buy
+2,867
New +$55.7K ﹤0.01% 1518
2018
Q3 		– Sell
-2,541
Closed -$40K – 4014
2018
Q2 		$38K Sell
2,541
-30,195
-92% -$538K ﹤0.01% 1775
2018
Q1 		$735K Buy
32,736
+18,365
+128% +$508K 0.06% 299
2017
Q4 		$432K Sell
14,371
-2,773
-16% -$88.7K 0.02% 608
2017
Q3 		$645K Sell
17,144
-12,290
-42% -$400K 0.02% 524
2017
Q2 		$820K Sell
29,434
-17,739
-38% -$529K 0.03% 475
2017
Q1 		$1.62M Buy
47,173
+35,976
+321% +$1.27M 0.07% 244
2016
Q4 		$322K Sell
11,197
-13,653
-55% -$361K 0.01% 970
2016
Q3 		$790K Buy
24,850
+8,908
+56% +$302K 0.04% 414
2016
Q2 		$517K Buy
15,942
+11,933
+298% +$399K 0.03% 573
2016
Q1 		$112K Sell
4,009
-40,379
-91% -$880K 0.01% 1506
2015
Q4 		$1.58M Buy
+44,388
New +$1.56M 0.09% 216

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Cutler Group's ACAD Position: Q3 2022 in Review

Cutler Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 800 shares — an estimated $13K sold.

Cutler Group first reported a position in ACAD in Q4 2015 and held it in 21 quarters. The position peaked at $1.62M in Q1 2017. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

  • Cutler Group reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 800 Acadia Pharmaceuticals shares in Q3 2022, an estimated $13K.
  • Cutler Group first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 21 quarters.
  • Cutler Group's Acadia Pharmaceuticals position peaked at $1.62M in Q1 2017.
  • 223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.